Regulatory Lilly bags FDA okay for Wegovy pill rival orforglipron PharmaphorumEli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill. RegulatoryMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo RivalryNext: FDA approves Lilly obesity pill, triggering battle with Novo Nordisk Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
